| Literature DB >> 28538688 |
Camila de Albuquerque Montenegro1,2, Gregório Fernandes Gonçalves3, Abrahão Alves de Oliveira Filho4, Andressa Brito Lira5, Thays Thyara Mendes Cassiano6, Natanael Teles Ramos de Lima7, José Maria Barbosa-Filho8,9, Margareth de Fátima Formiga Melo Diniz10,11, Hilzeth Luna Freire Pessôa12.
Abstract
Flavonoid compounds are widely used as natural protective species, which can act as anti-inflammatory, antioxidant, anticoagulant, antihypertensive and antitumor agents. This study set out to investigate the probable pharmacological activities, along with the antibacterial and antioxidant effects, of flavone and its hydroxy derivatives: 3-hydroxyflavone, 5-hydroxyflavone and 6-hydroxyflavone. To do so, we investigated their pharmacological characteristics, using in silico tests that indicate likelihood of activity or inactivity, with the PASS online software, and the antimicrobial potential against Gram positive and Gram negative bacteria was also analyzed, including bacteria of clinical importance. We also tested for oxidant and antioxidant potential in these molecules in the presence of reactive oxygen species (ROS) and phenylhydrazine (Ph). The results revealed the following characteristics: pharmacological activities for the flavonoids as agonists of cell membrane integrity and as permeability inhibitors, as antagonists of anaphylatoxin receptors, as inhibitors of both kinase and peroxidase, and as having both antimutagenic capacity and vaso-protective potential. All of the flavonoids exhibited moderate antibacterial activity against Gram positive and Gram negative strains, with the flavones being bactericidal at 200 μg/mL for the strains of P. aeruginosa ATCC 8027, S. aureus ATCC 25619 and E. coli 104; the other flavonoids revealed bacteriostatic action. The substances did not promote erythrocyte oxidation and behaved as sequestrators and antioxidants of hydrogen peroxide (H₂O₂) and phenylhydrazine (Ph). It was concluded that the analyzed compounds have various pharmacological activities in accordance with the predictions of PASS online, as their antibacterial and antioxidant activities were confirmed. The study also helps to consolidate the use of computational chemistry in silico tools to guide new drug search and discovery protocols.Entities:
Keywords: PASS online; antibacterials; antioxidants; flavonoids
Mesh:
Substances:
Year: 2017 PMID: 28538688 PMCID: PMC6152620 DOI: 10.3390/molecules22060869
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structure of flavone and its hydroxylated derivatives.
Suggestions of biological activities for flavone at Pa > 78.7%—second analysis by PASS online tool.
| PA | PI | Activity |
|---|---|---|
| 0.952 | 0.001 | Inhibitor of 4-nitrophenol 2-monooxygenase |
| 0.952 | 0.003 | HIF1A expression inhibitor |
| 0.947 | 0.004 | Agonist of membrane integrity |
| 0.943 | 0.002 | Inhibitor 27-hydroxycholesterol 7α-monooxygenas |
| 0.938 | 0.002 | Kinase inhibitor |
| 0.933 | 0.002 | Inhibitor of colestanetriol 26-monooxygenase |
| 0.929 | 0.003 | Anaphylatoxin receptor antagonist |
| 0.914 | 0.003 | Inhibitor of membrane permeability |
| 0.913 | 0.004 | Chlordecone reductase inhibitor |
| 0.913 | 0.009 | CYP2C12 substrate |
| 0.903 | 0.002 | CYP2B5 substrate |
| 0.895 | 0.002 | Aryl-alcohol dehydrogenase (NADP+) inhibitor |
| 0.893 | 0.002 | CYP1A2 inducer |
| 0.874 | 0.014 | Aspulvinone dimethylallyltransferase inhibitor |
| 0.872 | 0.002 | Inhibitor of P-benzoquinone reductase (NADPH) |
| 0.857 | 0.004 | Inhibitor of 2-dehydropantoate 2-reductase |
| 0.857 | 0.006 | Aldehyde oxidase inhibitor |
| 0.854 | 0.003 | CYP1A inducer |
| 0.850 | 0.012 | Methylenetetrahydrofolate reductase inhibitor (NADPH) |
| 0.849 | 0.004 | Vasoprotector |
| 0.848 | 0.002 | CYP2A4 substrate |
| 0.829 | 0.002 | Quercetin 2.3-dioxygenase inhibitor |
| 0.829 | 0.002 | Inhibitor of Leukotriene-B4 20-monooxygenase |
| 0.820 | 0.005 | Inhibitor of complement factor D |
| 0.819 | 0.005 | Alkane 1-monooxygenase inhibitor |
| 0.814 | 0.003 | CYP2A11 substrate |
| 0.813 | 0.018 | CYP2J substrate |
| 0.813 | 0.022 | Testosterone 17beta-dehydrogenase (NADP+) inhibitor |
| 0.809 | 0.002 | CYP1A1 inducer |
| 0.807 | 0.003 | MAP kinase stimulant |
| 0.806 | 0.006 | Inhibitor of oxidoreductase |
| 0.804 | 0.005 | Peroxidase inhibitor |
| 0.803 | 0.003 | Total ecdysone 20-monooxygenase inhibitor |
| 0.801 | 0.004 | Inhibitor of Pin1 |
| 0.800 | 0.018 | mucous membrane protector |
| 0.795 | 0.004 | Antimutagenic |
| 0.787 | 0.006 | Inhibitor of nitrate reductase (cytochrome) |
Pa = (probability “to be active”), Pi = (probability “to be inactive”).
Suggestions of biological activities for 3-hydroxyflavone at Pa > 79.8%—second analysis by PASS online tool.
| PA | PI | Activity |
|---|---|---|
| 0.962 | 0.003 | Agonist of membrane integrity |
| 0.957 | 0.003 | HIF1A expression inhibitor |
| 0.954 | 0.002 | Chlordecone reductase inhibitor |
| 0.947 | 0.001 | Aryl-alcohol dehydrogenase (NADP+) inhibitor |
| 0.947 | 0.002 | Kinase inhibitor |
| 0.939 | 0.003 | Inhibitor of membrane permeability |
| 0.938 | 0.001 | Inhibitor of |
| 0.929 | 0.001 | Quercetin 2.3-dioxygenase inhibitor |
| 0.922 | 0.002 | Inhibitor of 2-dehydropantoate 2-reductase |
| 0.917 | 0.002 | Peroxidase inhibitor |
| 0.896 | 0.009 | Aspulvinone dimethylallyltransferase inhibitor |
| 0.896 | 0.013 | CYP2C12 substrate |
| 0.894 | 0.002 | MAP kinase stimulant |
| 0.893 | 0.002 | CYP1A inducer |
| 0.892 | 0.002 | Colestanetriol inhibitor 26-monooxygenase |
| 0.889 | 0.002 | 2-Enoate reductase inhibitor |
| 0.888 | 0.002 | Inhibitor of 4-nitrophenol 2-monooxygenase |
| 0.888 | 0.007 | Inhibitor ubiquinol, cytochrome-c reductase |
| 0.880 | 0.005 | CYP1A substrate |
| 0.877 | 0.003 | Inhibitor of alcohol dehydrogenase (NADP+) |
| 0.876 | 0.002 | Inhibitor of NADPH-ferrihemoprotein reductase |
| 0.870 | 0.003 | Antimutagenic |
| 0.870 | 0.003 | Inhibitor 27-hydroxycholesterol 7α-monooxygenase |
| 0.861 | 0.002 | CYP1A1 inducer |
| 0.859 | 0.007 | Enhances expression of TP53 |
| 0.856 | 0.011 | Methylenetetrahydrofolate reductase inhibitor (NADPH) |
| 0.843 | 0.004 | CYP1A1 substrate |
| 0.843 | 0.008 | Anaphylatoxin receptor antagonist |
| 0.837 | 0.001 | Inhibitor of glycerol dehydrogenase (NADP+) |
| 0.827 | 0.003 | Enhances expression of HMOX1 |
| 0.825 | 0.005 | CYP1A2 substrate |
| 0.819 | 0.004 | UGT1A9 substrate |
| 0.816 | 0.002 | Inhibitor of 2-dehydropantolactone reductase (A-specific) |
| 0.804 | 0.009 | Inhibitor dehydro-L-gulonate decarboxylase |
| 0.802 | 0.003 | Inhibitor of β-carotene 15.15'-monooxygenase |
| 0.800 | 0.005 | Inhibitor of nitrate reductase (cytochrome) |
| 0.800 | 0.008 | Agonist of apoptosis |
| 0.799 | 0.006 | Alkane 1-monooxygenase inhibitor |
| 0.798 | 0.021 | The substrate CYP2J |
Pa = (probability “to be active”), Pi = (probability “to be inactive”).
Suggestions of biological activities for 5-hydroxyflavone at Pa > 79.5%—second analysis by PASS online tool.
| PA | PI | Activity |
|---|---|---|
| 0.963 | 0.003 | Agonist of membrane integrity |
| 0.956 | 0.002 | Chlordecone reductase inhibitor |
| 0.953 | 0.003 | HIF1A expression inhibitor |
| 0.942 | 0.005 | Substrate of CYP2C12 |
| 0.937 | 0.003 | Inhibitor of membrane permeability |
| 0.935 | 0.002 | Kinase inhibitor |
| 0.934 | 0.003 | Anaphylatoxin receptor antagonist |
| 0.930 | 0.001 | Aryl alcohol dehydrogenase inhibitor (NADP+) |
| 0.923 | 0.004 | Aldehyde oxidase inhibitor |
| 0.921 | 0.002 | Inhibitor of P-benzoquinone reductase (NADPH) |
| 0.920 | 0.003 | Inhibitor 2-dehydropantoate 2-reductase |
| 0.909 | 0.002 | Inhibitor of 4-nitrophenol 2-monooxygenase |
| 0.904 | 0.002 | Colestanetriol 26-monooxygenase inhibitor |
| 0.903 | 0.001 | Quercetin 2.3-dioxygenase inhibitor |
| 0.901 | 0.003 | Vasoprotector |
| 0.900 | 0.008 | Aspulvinone dimethylallyltransferase inhibitor |
| 0.897 | 0.002 | CYP1A inducer |
| 0.897 | 0.002 | Histidine kinase inhibitor |
| 0.895 | 0.003 | Inhibitor 27-hydroxycholesterol 7α-monooxygenase |
| 0.888 | 0.003 | Peroxidase inhibitor |
| 0.887 | 0.008 | Inhibitor of ubiquinol-cytochrome-c reductase |
| 0.882 | 0.002 | Antimutagenic |
| 0.880 | 0.002 | Inhibitor of NADPH-ferrihemoprotein reductase |
| 0.878 | 0.005 | CYP1A substrate |
| 0.871 | 0.007 | Enhances expression of TP53 |
| 0.868 | 0.002 | CYP1A1 inducer |
| 0.864 | 0.004 | UGT1A6 substrate |
| 0.854 | 0.003 | Inhibitor of alcohol dehydrogenase (NADP+) |
| 0.849 | 0.002 | 2-Enoate reductase inhibitor |
| 0.847 | 0.004 | Alkane 1-monooxygenase inhibitor |
| 0.842 | 0.003 | Enhances expression of HMOX1 |
| 0.841 | 0.002 | Inhibitor of β-carotene 15.15′-monooxygenase |
| 0.840 | 0.004 | UGT1A9 substrate |
| 0.838 | 0.001 | Inhibitor of glycerol dehydrogenase (NADP+) |
| 0.838 | 0.012 | Anti-seborrheic |
| 0.837 | 0.005 | CYP1A1 substrate |
| 0.835 | 0.003 | CYP2B5 substrate |
| 0.830 | 0.003 | CYP2A4 substrate |
| 0.827 | 0.003 | Inhibitor of Pin1 |
| 0.818 | 0.002 | SULT1A3 substrate |
| 0.814 | 0.008 | Inhibitor dihydrocholic L-gulonate decarboxylase |
| 0.812 | 0.002 | Inhibitor of Leukotriene-B4 20-monooxygenase |
| 0.807 | 0.008 | Agonist of apoptosis |
| 0.806 | 0.003 | Inhibitor of histamine release |
| 0.804 | 0.003 | Inhibitor of nitrite reductase [NAD(P)H] |
| 0.802 | 0.002 | Inhibitor 2-dehydropantolactone reductase (A-specific) |
| 0.795 | 0.003 | MAP kinase stimulant |
Pa = (probability “to be active”), Pi = (probability “to be inactive”).
Suggestions of biological activities for 6-hydroxyflavone at Pa > 79.2%—second analysis by PASS online tool.
| PA | PI | Activity |
|---|---|---|
| 0.957 | 0.003 | Agonist of membrane integrity |
| 0.949 | 0.002 | Chlordecone reductase inhibitor |
| 0.948 | 0.004 | HIF1A expression inhibitor |
| 0.945 | 0.004 | CYP2C12 substrate |
| 0.935 | 0.003 | Inhibitor of membrane permeability |
| 0.932 | 0.001 | Aryl alcohol dehydrogenase inhibitor (NADP+) |
| 0.932 | 0.001 | Inhibitor of 4-nitrophenol 2-monooxygenase |
| 0.929 | 0.003 | Inhibitor aldehyde oxidase |
| 0.924 | 0.002 | Inhibitor of |
| 0.915 | 0.002 | Inhibitor colestanetriol 26-monooxygenase |
| 0.914 | 0.003 | Kinase inhibitor |
| 0.907 | 0.002 | Inhibitor 27-Hydroxycolesterol 7α-monooxygenase |
| 0.901 | 0.003 | Inhibitor 2-2-dehydropantoate reductase |
| 0.895 | 0.004 | Anaphylatoxin receptor antagonist |
| 0.894 | 0.002 | CYP1A inducer |
| 0.892 | 0.003 | Peroxidase inhibitor |
| 0.888 | 0.002 | Antimutagenic |
| 0.887 | 0.011 | Aspulvinone dimethylallyltransferase inhibitor |
| 0.884 | 0.002 | MAP kinase stimulant |
| 0.880 | 0.001 | Quercetin 2.3-dioxygenase inhibitor inhibitor |
| 0.875 | 0.006 | Anti-seborreic |
| 0.868 | 0.002 | CYP1A1 inducer |
| 0.852 | 0.007 | Enhances expression of TP53 |
| 0.851 | 0.005 | CYP1A substrate |
| 0.850 | 0.003 | Inhibitor of NADPH-ferrihemoprotein reductase |
| 0.850 | 0.003 | CYP2B5 substrate |
| 0.844 | 0.003 | Enhances expression of HMOX1 |
| 0.843 | 0.003 | CYP2A4 substrate |
| 0.843 | 0.004 | UGT1A9 substrate |
| 0.840 | 0.003 | Inhibitor of Pin1 |
| 0.840 | 0.004 | Vasoprotector |
| 0.841 | 0.005 | Expression of JAK2 inhibitor |
| 0.833 | 0.003 | Inhibitor of alcohol dehydrogenase (NADP+) |
| 0.829 | 0.002 | Inhibitor of leukotriene-B4 20-monooxygenase |
| 0.828 | 0.005 | Alkane 1-monooxygenase inhibitor |
| 0.822 | 0.005 | Inhibitor of oxidoreductase |
| 0.820 | 0.016 | Methylenetetrahydrofolate reductase inhibitor (NADPH) |
| 0.817 | 0.005 | Substrate of CYP1A1 |
| 0.815 | 0.003 | Inhibitor of β-carotene 15.15′-monooxygenase |
| 0.815 | 0.004 | Histidine kinase inhibitor |
| 0.809 | 0.002 | 2-Enoate reductase inhibitor |
| 0.809 | 0.013 | 5 Hydroxytryptamine release stimulant |
| 0.808 | 0.003 | Inhibitor of nitrite reductase [NAD (P) H] |
| 0.806 | 0.004 | UGT1A6 substrate |
| 0.805 | 0.017 | Mucous membrane protector |
| 0.802 | 0.016 | Gluconate 2-dehydrogenase inhibitor |
| 0.801 | 0.002 | Inhibitor of Glycerol dehydrogenase (NADP+) |
| 0.797 | 0.002 | CYP1A2 inducer |
| 0.797 | 0.003 | Inhibitor of histamine release |
Pa = (probability “to be active”), Pi = (probability “to be inactive”).
Antibacterial activity (μg/mL) of flavonoids flavone, 3-hydroxyflavone, 3-hydroxyflavone and 3-hydroxyflavone against Gram-positive strains.
| Test Group | Flavone | 3-Hydroxyflavone | 5-Hydroxyflavone | 6-Hydroxyflavone | Chloramphenicol | DMSO | |
|---|---|---|---|---|---|---|---|
| Bacteria | |||||||
| >200 | 200 | >200 | >200 | 100 | + | ||
| 100 | 100 | 200 | 200 | 100 | + | ||
| 200 | 200 | >200 | >200 | 100 | + | ||
+: Growth.
Antibacterial activity (μg/mL) of flavonoids flavone, 3-hydroxyflavone, 5-hydroxyflavone and 6-hydroxyflavone against Gram-negative strains.
| Test Group | Flavone | 3-Hydroxyflavone | 5-Hydroxyflavone | 6-Hydroxyflavone | Chloramphenicol | DMSO | |
|---|---|---|---|---|---|---|---|
| Bacteria | |||||||
| 200 | 200 | >200 | >200 | 100 | + | ||
| 50 | 200 | 200 | 200 | 100 | + | ||
| 100 | 100 | 200 | >200 | 100 | + | ||
| 100 | 200 | 200 | 200 | 100 | + | ||
| 25 | 200 | >200 | >200 | 100 | + | ||
| 200 | 100 | 200 | >200 | 100 | + | ||
| 25 | 200 | 200 | >200 | 100 | + | ||
| 200 | 100 | 25 | 200 | 100 | + | ||
Figure 2Antioxidant activity of flavonoids flavone (a), 3-hydroxyflavone (b), 5-hydroxyflavone (c) and 6-hydroxyflavone (d) against hemolysis induced by hydrogen peroxide in blood of type O+. The results are expressed as a percentage of the average in comparison to the positive control group (Hb + H2O2). Analysis by ANOVA followed by Dunnett post-test. * p < 0.05, ** p < 0.01, *** p < 0.001 (n = 3).
Figure 3Oxidant (a) and antioxidant (b) effects of flavone on human erythrocytes. The results are expressed as a percentage of the average formation of methemoglobin (MetHb) compared to the negative control (oxidant) and positive control (antioxidant) groups. Analysis by ANOVA followed by Dunnett post-test. *** p < 0.001 (n = 3).
Figure 4Oxidant (a) and antioxidant (b) effects of 3-hydroxyflavone on human erythrocytes. The results are expressed as a percentage of the average formation of methemoglobin (MetHb) compared to the negative control (oxidant) and positive control (antioxidant) groups. Analysis by ANOVA followed by Dunnett post-test. ** p < 0.001 (n = 3).
Figure 5Oxidant (a) and antioxidant (b) effects of 5-hydroxyflavone on human erythrocytes. The results are expressed as a percentage of the average formation of methemoglobin (MetHb) compared to the negative control (oxidant) and positive control (antioxidant) groups. Analysis by ANOVA followed by Dunnett post-test. *** p < 0.001 (n = 3).
Figure 6Oxidant (a) and antioxidant (b) effects of 6-hydroxyflavone on human erythrocytes. The results are expressed as a percentage of the average formation of methemoglobin (MetHb) compared to the negative control (oxidant) and positive control (antioxidant) groups. Analysis by ANOVA followed by Dunnett post-test. *** p < 0.001 (n = 3).